FBX-101

BIOLOGICAL4 trials

Sponsors

Forge Biologics Inc., Forge Biologics, Inc

Conditions

Krabbe Disease

Phase 1

Gene Transfer Clinical Trial for Krabbe Disease

Active, not recruitingNCT04693598

Forge Biologics, IncKrabbe Disease

Start: 2021-11-05End: 2026-11-01Target: 6Updated: 2026-06-02

Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT

Active, not recruitingNCT05739643

Forge Biologics, IncKrabbe Disease

Start: 2023-02-03End: 2026-11-30Target: 9Updated: 2025-11-20

A Phase 1/2 Clinical Study of Intravenous Gene Transfer with an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE)

WithdrawnCTIS2023-504900-28-00

Forge Biologics Inc.Krabbe Disease

Target: 2Updated: 2023-08-04

Unknown Phase

Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients

TerminatedNCT06308718

Forge Biologics, IncKrabbe Disease

Start: 2024-08-06End: 2025-04-11Updated: 2025-09-05

Related Papers

Combination HSCT and intravenous AAV-mediated gene therapy in a canine model proves pivotal for translation of Krabbe disease therapy.

2023-11-116 citations

Preclinical studies in Krabbe disease: A model for the investigation of novel combination therapies for lysosomal storage diseases.

2022-10-0413 citations